

Claims

What is claimed :

1. A method of treating a subject in need of modulating the activity of aldose reductase comprising a step of administering the subject with a pharmaceutical dose of fibrate.
2. The method of claim 1 wherein the fibrate is bezafibrate.
3. The method of claim 1 wherein the fibrate is selected from the group consisting of clofibric acid, ciprofibrate, gemfibrizil, fenofibrate.
4. The method of claim 1 wherein the subject has a condition selected from the group consisting of cardiovascular disease, diabetes, arteriosclerosis, cancer, neoplasm, cataract, retinopathy, keratopathy, nephropathy, neurosis, thrombosis, faulty union of corneal injury and neuropathy.
5. The method of claim 1 further comprising a step of co-administering the subject with a chemotherapeutics.
6. A method of treating a neoplasm comprising a step of contacting a neoplasm cell with fibrate.
7. The method of claim 6 wherein the fibrate is bezafibratethe.
8. The method of claim 6 wherein the fibrate is selected from the group consisting of ciprofibrate, gemfibrizil, fenofibrate.
9. The method of claim 6 wherein the neoplasm is selected from the group consisting of tumor, cancer, fibromas, melanomas, carcinomas, adenocarcinomas, sarcomas, lymphomas, and leukemias.

10. The method of claim 6 further comprising a step of co-contacting the cell with a chemotherapeutics.
11. A method of modulating the activity of aldose reductase in a cell comprising a step of contacting the cell with fibrate.
- 5 12. The method of claim 11 wherein the fibrate is bezafibrate.
13. The method of claim 11 wherein the fibrate is selected from the group consisting of clofibric acid, ciprofibrate, gemfibrizil, fenofibrate.